EUVIMEDSkopri EUVIMED
Open access · CC BY 4.0

Subclassification of epithelioid sarcoma with potential therapeutic impact

Simon Haefliger iD, Olga Chervova, Christopher Davies, Steven Nottley, Steven Hargreaves, Vaiyapuri P Sumathi, Fernanda Amary, Roberto Tirabosco, Nischalan Pillay, Stephan Beck, Adrienne M Flanagan iD, Iben Lyskjaer

The Journal of Pathology · 2023

DOI: 10.1002/path.6135 ↗

At a glance

Journal article in The Journal of Pathology, 2023. Written by Simon Haefliger and 11 co-authors. Institution: Research Department of Pathology, University College London, UCL Cancer Institute, London, UK. Major MEDLINE topics: Rhabdoid Tumor, Sarcoma. Cited 12 times so far (Crossref); 21 references. The full text is freely available (open access, CC BY 4.0). Funded by: Department of Health, Cancer Research UK, Lundbeck Foundation.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Epithelioid sarcoma is a rare and aggressive mesenchymal tumour, the genetic hallmark of which is the loss of expression of SMARCB1 , a key member of the SWItch/Sucrose Non‐Fermentable (SWI/SNF) chromatin remodelling complex. Hampered by its rarity, epithelioid sarcoma has received little research attention and therapeutic options for this disease remain limited. SMARCB1 ‐deficient tumours also include malignant rhabdoid tumour, atypical teratoid and rhabdoid tumour, epithelioid malignant peripheral nerve sheath tumour, and poorly differentiated chordoma. Histologically, it can be challenging to distinguish epithelioid sarcoma from malignant rhabdoid tumour and other SMARCB1‐ deficient tumours, whereas methylation profiling shows that they represent distinct entities and facilitates their classification. Methylation studies on SMARCB1 ‐deficient tumours, although not including epithelioid sarcomas, reported methylation subgroups which resulted in new clinical stratification and therapeutic approaches. In addition, emerging evidence indicates that immunotherapy, including immune checkpoint inhibitors, represents a promising therapeutic strategy for SMARCB1‐ deficient tumours. Here, we show that some epithelioid sarcomas share methylation patterns of malignant rhabdoid tumours indicating that this could help to distinguish these entities and guide treatment. Using gene expression data, we also showed that the immune environment of epithelioid sarcoma is characterised by a predominance of CD8 + lymphocytes and M2 macrophages. These findings have potential implications for the management of patients with epithelioid sarcoma. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Subjects

MeSH terms (MEDLINE)

Rhabdoid TumorSarcomaHumansDNA-Binding ProteinsChromosomal Proteins, Non-HistoneImmunohistochemistrySMARCB1 Protein

Author keywords

DNA methylation profileSMARCB1SMARCB1-deficient tumoursepithelioid sarcomaimmune cell deconvolution

Substances

DNA-Binding ProteinsChromosomal Proteins, Non-HistoneSMARCB1 Protein

Authors and institutions

  • Research Department of Pathology, University College London, UCL Cancer Institute, London, UK.
  • Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.
  • Department of Histopathology, Royal National Orthopaedic Hospital, Stanmore, UK.
  • Medical Genomics Research Group, University College London, UCL Cancer Institute, London, UK.
  • The Royal Orthopaedic Hospital, Birmingham, UK.
  • Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.

ORCID profiles: Simon Haefliger, Adrienne M Flanagan

Funding

  • Department of Health
  • Cancer Research UK
  • Lundbeck Foundation
  • National Institute for Health and Care Research
  • Sarcoma UK

Cite

APA

Haefliger, S., Chervova, O., Davies, C., Nottley, S., Hargreaves, S., Sumathi, V. P., Amary, F., Tirabosco, R., Pillay, N., Beck, S., Flanagan, A. M., & Lyskjaer, I. (2023). Subclassification of epithelioid sarcoma with potential therapeutic impact. The Journal of Pathology. https://doi.org/10.1002/path.6135

Vancouver

Haefliger S, Chervova O, Davies C, Nottley S, Hargreaves S, Sumathi VP, et al. Subclassification of epithelioid sarcoma with potential therapeutic impact. The Journal of Pathology. 2023. doi:10.1002/path.6135

BibTeX
@article{Haefliger2023,
  author = {Haefliger, Simon and Chervova, Olga and Davies, Christopher and Nottley, Steven and Hargreaves, Steven and Sumathi, Vaiyapuri P and Amary, Fernanda and Tirabosco, Roberto and Pillay, Nischalan and Beck, Stephan and Flanagan, Adrienne M and Lyskjaer, Iben},
  title = {Subclassification of epithelioid sarcoma with potential therapeutic impact},
  journal = {The Journal of Pathology},
  year = {2023},
  doi = {10.1002/path.6135}
}
Start for free →